Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash from Financing Activities (2023 - 2025)

Monte Rosa Therapeutics' Cash from Financing Activities history spans 3 years, with the latest figure at $29.6 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 4772.37% year-over-year to $29.6 million; the TTM value through Dec 2025 reached $30.4 million, down 69.31%, while the annual FY2025 figure was $30.4 million, 69.31% down from the prior year.
  • Cash from Financing Activities reached $29.6 million in Q4 2025 per GLUE's latest filing, up from $348000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $98.0 million in Q2 2024 to a low of $14000.0 in Q1 2025.
  • Average Cash from Financing Activities over 3 years is $13.1 million, with a median of $486500.0 recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 8068.58% in 2024, then crashed 99.63% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at $25.2 million in 2023, then plummeted by 97.58% to $608000.0 in 2024, then soared by 4772.37% to $29.6 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Cash from Financing Activities are $29.6 million (Q4 2025), $348000.0 (Q3 2025), and $365000.0 (Q2 2025).